Cyclovirobuxine‐D (CVB‐D) was identified as the first LIF inhibitor in HCC, which binding LIF at Val145, showed therapeutic potential in both nude mouse and patient‐derived xenograft (PDX) models by inducing mitophagy, cell cycle arrest, suggesting a therapeutic potential drug for future cancer treatment. Here, LIF is linked to hepatocellular carcinoma.